TABLE 4.
Summary of the results of chromosome aberrations of Symbiota® (MS‐20) in CHO cells.
| Condition | Treatment (μL/mL) | Duration (h) | S9 (−/+) | Survival (%) a | Aberrant cells (%) |
|---|---|---|---|---|---|
| Scheme I (‐S9, 3 h) | |||||
| Vehicle | 0 | 3 | − | 100.0 | 0 |
| 6.25 | 6.25 | 3 | − | 91.8 | 0 |
| 12.5 | 12.5 | 3 | − | 65.5 | 0 |
| 25 | 25 | 3 | − | 62.4 | 0.5 |
| 50 | 50 | 3 | − | 48.8 | 0.5 |
| 100 | 100 | 3 | − | 31.2 | Too few metaphases |
| Positive b | − | 3 | − | NA | 23 |
| Scheme II (+S9, 3 h) | |||||
| Vehicle | 0 | 3 | + | 100.0 | 0 |
| 6.25 | 6.25 | 3 | + | 99.3 | 0 |
| 12.5 | 12.5 | 3 | + | 90.8 | 0 |
| 25 | 25 | 3 | + | 88.7 | 0 |
| 50 | 50 | 3 | + | 77.3 | 1 |
| 100 | 100 | 3 | + | 59.6 | 2.5 |
| Positive c | − | 3 | + | NA | 18.5 |
| Scheme III (‐S9, 20 h) | |||||
| Vehicle | 0 | 20 | − | 100.0 | 0 |
| 6.25 | 6.25 | 20 | − | 96.2 | 0 |
| 12.5 | 12.5 | 20 | − | 82.6 | 0 |
| 25 | 25 | 20 | − | 58.7 | 0 |
| 50 | 50 | 20 | − | 15.2 | Too few metaphases |
| 100 | 100 | 20 | − | 0.0 | Too few metaphases |
| Positive b | − | 20 | − | NA | 22.5 |
a
The concurrent cytotoxicity of test product was assessed in duplicate cultures.
b
Positive control: Mitomycin C at 1 μM.
c
Positive control: Cyclophosphamide at 40 μM.